Antiemetic-regimen with fosaprepitant injection provides correspond to patronage against CINV as said EMEND
Merck announced today results from a different non-inferiority trial run of an antiemetic regimen containing fosaprepitant dimeglumine administered as a individual intravenous (IV) 150-mg administer in blend with a 5-HT3 opposition and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 adversary and dexamethasone in the direction of the interdicting of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a anything else course of cisplatin-based chemotherapy. The regimen containing 150 mg fosaprepitant dimeglumine was not bad to the regimen with articulated aprepitant. Results of the deliberate over, known as EASE-017, intent be presented on June 8th at the 2010 American Fellowship of Clinical Oncology (ASCO) annual confluence in Chicago, during a bull session on the notice titled "Phase III randomized double-blind reflect on of single-dose fosaprepitant respecting delaying of cisplatin-induced nausea and vomiting."
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
